Opendata, web and dolomites

B2B SIGNED

Modeling spontaneous Breast cancer metastasis TO the Bone with a first-of-its-kind 3D device that recapitulates physiological tissue-level complexity.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 B2B project word cloud

Explore the words cloud of the B2B project. It provides you a very rough idea of what is the project "B2B" about.

spontaneous    screening    clinically    patient    barrier    passing    tissue    b2b    vascularized    overcome    cell    3d    hierarchical    model    device    transcend    cells    circulating    recapitulate    tree    patients    woman    assembled    date    bone    cancer    ones    empower    networks    dynamics    organoids    physiological    found    identification    consequently    million    ossicle    site    throughput    size    first    connected    spanning    limitations    drugs    single    drug    fold    breakthrough    containing    agents    metastatic    repurposing    micro    incurable    tumor    generate    breast    composition    hits    self    longitudinally    pursue    propagate    technologies    marrow    ossicles    continuum    hurdle    mortality    context    comprising    therapies    hierarchically    dissect    capillary    macro    circuit    metastasis    lack    branched    dimensions    endothelial    newly    bioprinted    nor    vascular    disease    linked    suppressing    hybrid    closed    structure    spread    vitro    complexity   

Project "B2B" data sheet

The following table provides information about the project.

Coordinator
CONSIGLIO NAZIONALE DELLE RICERCHE 

Organization address
address: PIAZZALE ALDO MORO 7
city: ROMA
postcode: 185
website: www.cnr.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.b2bproject.eu
 Total cost 3˙799˙371 €
 EC max contribution 3˙799˙371 € (100%)
 Programme 1. H2020-EU.1.2.1. (FET Open)
 Code Call H2020-FETOPEN-1-2016-2017
 Funding Scheme RIA
 Starting year 2018
 Duration (year-month-day) from 2018-07-01   to  2022-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSIGLIO NAZIONALE DELLE RICERCHE IT (ROMA) coordinator 711˙887.00
2    UNIVERSITAT BASEL CH (BASEL) participant 1˙198˙345.00
3    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 464˙383.00
4    REACT4LIFE SRL IT (GENOVA) participant 406˙600.00
5    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 390˙825.00
6    CAMBRIDGE INNOVATION TECHNOLOGIES CONSULTING LIMITED UK (CAMBRIDGE) participant 234˙242.00
7    IN SRL IT (UDINE) participant 230˙587.00
8    BIOEMISSION TECHNOLOGY SOLUTIONS IKE EL (ATHINA) participant 162˙500.00

Map

 Project objective

Cancer patients developing a metastatic disease are considered incurable. Breast cancer hits 1 woman in 8, and its most common metastatic site is the bone. A major hurdle to overcome breast cancer mortality is the lack of understanding of dynamics leading to the spread of breast cancer cells to the bone. Consequently, metastasis-suppressing agents have not been found to date, neither as newly developed drugs nor as repurposing of existing ones. The aim of the B2B device is to generate a first-of-a-kind 3D model of spontaneous breast cancer metastasis to the bone to dissect the complexity of the metastatic process and empower high-throughput drug screening in a physiological context. B2B will pursue its goal of developing a novel hybrid device able to 1) propagate patient-derived tumor organoids of clinically-relevant dimensions, with their own self-assembled micro-capillary networks, which are 2) continuously linked to a 3D bioprinted macro-vascular tree, organized in a hierarchical branched structure, connected in a closed circuit with 3) a vascularized marrow-containing bone ossicle, as the metastatic target. This is a unique approach, spanning the micro (single circulating metastatic cells, passing the endothelial barrier of capillary networks) to macro (tumor organoids and ossicles of clinically relevant size and tissue composition, connected by a hierarchically organized vascular tree) continuum to recapitulate spontaneous bone metastasis formation in breast cancer. This technology will transcend the limitations of current in vitro technologies, enabling physiological tissue-level complexity with organoids comprising several million cells, and its expected impact will be three-fold: to recapitulate the spontaneous metastatic process in breast cancer, to provide a breakthrough technology to investigate metastasis longitudinally and at the single cell level, and to lead to the identification of metastasis-suppressing therapies for breast cancer patients.

 Deliverables

List of deliverables.
Website and logo Websites, patent fillings, videos etc. 2019-10-08 17:12:39

Take a look to the deliverables list in detail:  detailed list of B2B deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 Francesc Castro-Giner, Sofia Gkountela, Cinzia Donato, Ilaria Alborelli, Luca Quagliata, Charlotte Ng, Salvatore Piscuoglio, Nicola Aceto
Cancer Diagnosis Using a Liquid Biopsy: Challenges and Expectations
published pages: 31, ISSN: 2075-4418, DOI: 10.3390/diagnostics8020031
Diagnostics 8/2 2019-08-29

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "B2B" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "B2B" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.2.1.)

FRINGE (2019)

Fluorescence and Reactive oxygen Intermediates by Neutron Generated electronic Excitation as a foundation for radically new cancer therapies

Read More  

BRIEFING (2018)

Bridging the FET Innovation Gap

Read More  

ALICE (2019)

Active Living Infrastructure: Controlled Environment

Read More